Analysts expect that ArQule, Inc. (NASDAQ:ARQL) will post earnings per share (EPS) of ($0.06) for the current quarter, according to Zacks. Four analysts have provided estimates for ArQule’s earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.10). ArQule reported earnings of ($0.09) per share during the same quarter last year, which suggests a positive year over year growth rate of 33.3%. The business is expected to report its next quarterly earnings report on Thursday, November 8th.

According to Zacks, analysts expect that ArQule will report full-year earnings of ($0.12) per share for the current financial year, with EPS estimates ranging from ($0.16) to ($0.05). For the next financial year, analysts expect that the company will post earnings of ($0.28) per share, with EPS estimates ranging from ($0.41) to ($0.10). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for ArQule.

ArQule (NASDAQ:ARQL) last announced its earnings results on Wednesday, August 1st. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.02. The company had revenue of $13.71 million during the quarter, compared to the consensus estimate of $7.70 million. During the same quarter in the prior year, the company earned ($0.12) EPS.

A number of equities analysts recently issued reports on ARQL shares. Needham & Company LLC increased their target price on shares of ArQule from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, June 18th. ValuEngine lowered shares of ArQule from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 16th. BidaskClub lowered shares of ArQule from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 12th. Zacks Investment Research upgraded shares of ArQule from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research report on Monday, July 9th. Finally, B. Riley increased their target price on shares of ArQule from $4.00 to $7.50 and gave the company a “buy” rating in a research report on Friday, June 29th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $6.65.

A number of institutional investors and hedge funds have recently made changes to their positions in ARQL. Jane Street Group LLC bought a new position in ArQule in the 1st quarter valued at about $100,000. CAPROCK Group Inc. acquired a new stake in ArQule in the 2nd quarter valued at about $109,000. Zebra Capital Management LLC acquired a new stake in ArQule in the 2nd quarter valued at about $115,000. Millennium Management LLC acquired a new stake in ArQule in the 4th quarter valued at about $165,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in ArQule in the 2nd quarter valued at about $169,000. Hedge funds and other institutional investors own 65.10% of the company’s stock.

Shares of ARQL opened at $6.13 on Tuesday. The company has a quick ratio of 5.99, a current ratio of 5.99 and a debt-to-equity ratio of 0.54. ArQule has a 52-week low of $0.97 and a 52-week high of $7.21.

ArQule Company Profile

ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions.

Recommended Story: Investing in Growth Stocks

Get a free copy of the Zacks research report on ArQule (ARQL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ArQule (NASDAQ:ARQL)

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.